CDC Website CDC Website

To Join the NPIN community or

You are here

Researchers

Silencing of HIV-1 Proviruses (R61/R33)

This Funding Opportunity Announcement (FOA) encourages Exploratory and developmental bi-phasic research applications to support the identification and optimization of small molecules or RNAs that interact with host epigenetic machinery to mediate long-term or permanent epigenetic silencing of HIV-1 proviruses.

Limited Interaction Targeted Epidemiology (LITE) to Advance HIV Prevention (UG3/UH3)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV infection: men who have sex with men (MSM), transgender women, and black/African American women. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. Funding for a UG3 phase will be used to enroll and follow sufficient numbers of high-risk HIV-negative participants to reach seroconversion milestone targets.

Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71)

The Fogarty HIV Research Training Program supports research training that strengthens HIV research capacity of institutions in low-and middle-income countries (LMIC). This FOA offers an opportunity for LMIC institutions to submit a planning grant application to participate in the Fogarty HIV Research Training Program. These applications must propose a plan to develop a research training program and the subsequent application that will be submitted in response to the companion D43 FOA (PAR-16-279).

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment protection/efficacy.

Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vac...

NPIN admin's picture
This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged.

Advancing the development and licensure of vaginal rings and innovative systemic methods for prevention of HIV infection in w...

NPIN admin's picture
The United States Agency for International Development (USAID) is seeking applications from qualified U.S. and Non-U.S. organizations to fund a project entitled “Advancing the development and licensure of vaginal rings and innovative systemic methods for prevention of HIV infection in women”. Two to four cooperative agreements are planned under this notice. Eligibility for these awards is not restricted (see Section C of this Notice of Funding Opportunity (NFO) for eligibility requirements).

The Use of mRNA for an HIV Envelope Vaccine (R43/R44)

NPIN admin's picture
The purpose of this Funding Opportunity Announcement (FOA) is to encourage Small Business Innovation Research (SBIR) grant applications from Small Business Concerns (SBCs) that will focus on the development of novel direct mRNA-based and self-amplifying mRNA-based HIV envelope vaccine platforms suitable for use in clinical research. Such technologies should have commercial potential.

Understanding HIV Rebound (P01)

NPIN admin's picture
The purpose of this Funding Opportunity Announcement (FOA) is to support multi-disciplinary, Program Project applications aimed at understanding specific mechanisms, biomarkers, and pathways associated with rebound of HIV viremia.

Pages

Subscribe to RSS - Researchers